GSK Hunts for Novelty By Paying £11m To Apeiron In A Respiratory Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately owned Austrian biotech attracts GSK to a Phase I ARDS biologic.
You may also be interested in...
Austria’s Apeiron To Attack COVID-19 At Its Entry Point
Deals Of The Week: GSK/Apeiron, Cephalon/Mepha, Medco/DNA Direct...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: GSK/Apeiron, Cephalon/Mepha, Medco/DNA Direct...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.